Found: 10
Select item for more details and to access through your institution.
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists.
- Published in:
- Obesity Reviews, 2024, v. 25, n. 3, p. 1, doi. 10.1111/obr.13663
- By:
- Publication type:
- Article
Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2017, v. 10, p. 317, doi. 10.2147/DMSO.S117982
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 10, p. 2192, doi. 10.1111/dom.13811
- By:
- Publication type:
- Article
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1316, doi. 10.1111/dom.13278
- By:
- Publication type:
- Article
Use of flash glucose monitoring is associated with HbA1c reduction in type 2 diabetes managed with basal insulin in Canada: A real-world prospective observational study.
- Published in:
- Diabetes & Vascular Disease Research, 2024, v. 21, n. 3, p. 1, doi. 10.1177/14791641241253967
- By:
- Publication type:
- Article
Emergency Room Visits: Comparison of Individuals with Type 1 and Type 2 Diabetes Against Individuals Without Diabetes.
- Published in:
- Diabetes, 2007, v. 56, p. A618
- By:
- Publication type:
- Article
Greater Combined Reductions of HbA<sub>1c</sub> ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 8, p. 1415, doi. 10.1007/s13300-023-01413-5
- By:
- Publication type:
- Article
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
- Published in:
- 2017
- By:
- Publication type:
- journal article
964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-964-P
- By:
- Publication type:
- Article
986-P: Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-986-P
- By:
- Publication type:
- Article